This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study designs and other criteria for inclusion in the review
The primary studies for the transitional probabilities were all randomised controlled trials, while a cross-sectional study was used for utility values.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
The evidence on the transitional probabilities used in the decision model, and the utility values used to calculate the quality-adjusted life-years (QALYs) were derived from five primary studies.
Methods of combining primary studies
The studies were combined using narrative methods.
Investigation of differences between primary studies
Not carried out.
Results of the review
The transitional probabilities for stage I (EDSS 2.5 to 4.5) were: 0.920 for continuation after the first cycle of IFNB (8 MIU for stage III, 0.31 for progression from EDSS 8.5 to death.
The annual frequencies for exacerbations were:
for stage I, 1.21 for placebo and 0.84 for interferon; and for stage II, 0.64 for placebo and 0.44 for interferon.
The utility values ranged from 0 (dead) to 0.71.
The utility loss due to relapse was 0.5.
Methods used to derive estimates of effectiveness
The authors made some assumptions to populate the decision model, due to the lack of published data.
Estimates of effectiveness and key assumptions
The probability value from EDSS 8.5 to death was assumed to be 0. The authors assumed that disease progression after the actual follow-up period was the same whether patients did or did not receive preventive treatment in stage III of the disease (EDSS 7.5 to 9.5), and that there was no difference in mortality in the two study groups. They also assumed that non-compliance occurred only during the first cycle of the decision model, and that patients in stage III did not experience any exacerbation and did not receive any benefit from IFNB.
Measure of benefits used in the economic analysis
The benefit measure in the economic analysis was QALYs. Utility weights were derived from a published study. No discounting of the benefits was performed.
Direct costs
The lifetime costs were discounted using a 6% rate from the second year onwards. The unit costs and the quantities of resources were not reported. The health services included in the economic evaluation were for medication and consultations. The cost/resource boundary for the direct costs was that of the NHS. The total expected costs of the interventions were calculated using modelling. The costs and quantities were estimated from two cross-sectional studies. All of the costs were inflated to 1998 values from 1996 using a 4.3% inflation correction.
Statistical analysis of costs
The costs were treated deterministically in the base-case analysis.
Indirect Costs
A 6% discount rate was used as the lifetime costs were estimated. Neither the unit costs nor the quantities of resources used were reported. The non-medical costs examined in the analysis were workdays lost, transportation, community assistance and home modifications. The cost/resource boundary adopted was that of society. The friction cost method was used to calculate the indirect costs, assuming a productivity loss that was 80% of the average value of a worker's productivity during the "friction period". The time lost by inactive patients was considered as leisure time lost and was valued at 40% of the average wage in UK. The care-giver's time was also included in the analysis. The authors made some assumptions on time lost due to relapse. The source of the cost data was the Office for National Statistics Earnings. The price year was 1998.
